2007
DOI: 10.1016/j.jacc.2007.07.070
|View full text |Cite
|
Sign up to set email alerts
|

Pioglitazone Improves Myocardial Blood Flow and Glucose Utilization in Nondiabetic Patients With Combined Hyperlipidemia

Abstract: In patients with FCHL treated with conventional lipid-lowering therapy, the addition of pioglitazone led to significant improvements in MGU and MBF, with a favorable effect on blood lipid and metabolic parameters. (A study to investigate the effect of pioglitazone on whole body and myocardial glucose uptake and myocardial blood flow/coronary vasodilator reserve in patients with familial combined hyperlipidaemia; http://www.controlled-trials.com/mrct/trial/230761/ISRCTN78563659; ISRCTN78563659).

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

3
21
0
1

Year Published

2009
2009
2018
2018

Publication Types

Select...
5
4
1

Relationship

1
9

Authors

Journals

citations
Cited by 43 publications
(25 citation statements)
references
References 41 publications
3
21
0
1
Order By: Relevance
“…Because thiazolidinediones such as pioglitazone and rosiglitazone act as insulin sensitizers, improvement of MGU in T2DM by these drugs might indicate the occurrence of myocardial insulin resistance in patients with T2DM. Similar results using pioglitazone were obtained by Naoumova et al [23].…”
Section: Main Part Of Review and Discussionsupporting
confidence: 89%
“…Because thiazolidinediones such as pioglitazone and rosiglitazone act as insulin sensitizers, improvement of MGU in T2DM by these drugs might indicate the occurrence of myocardial insulin resistance in patients with T2DM. Similar results using pioglitazone were obtained by Naoumova et al [23].…”
Section: Main Part Of Review and Discussionsupporting
confidence: 89%
“…In a randomized, double-blind, placebo-controlled study in 26 nondiabetic patients with familial combined hyperlipidemia, Naoumova et al (74) tested the effect of treatment with the insulin sensitizer thiazolidinedione pioglitazone added to conventional lipid-lowering therapy on myocardial glucose use and blood flow using PET with 18 F-FDG and H 2 15 O, respectively. After 16 wk of treatment, there was evidence of significant increases in myocardial glucose use and hyperemic blood flow with adenosine, again suggesting improved coronary microvascular function.…”
Section: Mbf and Coronary Microvascular Dysfunctionmentioning
confidence: 99%
“…Several studies have evaluated the effect of exercise, insulin infusion, or pharmacologic agents on skeletal muscle glucose utilization (SMGU) in type 2 diabetes mellitus patients (7)(8)(9). However, little to no information is known about within-subject (test-retest) and intersubject variability of glucose utilization in these metabolically active tissues under basal conditions in healthy humans.…”
mentioning
confidence: 99%